CHM 0.00% 1.0¢ chimeric therapeutics limited

the neurosurgeons need to be qualified to administer car t cell...

  1. 103 Posts.
    lightbulb Created with Sketch. 40
    the neurosurgeons need to be qualified to administer car t cell therapies (in our case dual intraventicular administration). Now given that car T cells have historically only been used for treating blood cancers, then it follows that neurosurgeons would not be experts in car T.

    importantly, there are a number of existing oncology therapies that involve intraventricular administration into the brain (to overcome the blood brain barrier).

    furthermore, given a successful car t treatment for glioblastoma would cost patients up to USD1m I don’t see why big pharma couldn’t train the relevant specialist. I mean the throw money at them for conferences etc
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.0¢
Change
0.000(0.00%)
Mkt cap ! $9.951M
Open High Low Value Volume
1.1¢ 1.2¢ 1.0¢ $38.54K 3.639M

Buyers (Bids)

No. Vol. Price($)
9 2646760 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 729690 4
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.